VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

EAN 2022 | Promising biomarkers in MS: serum NfL & GFAP

Biomarkers can be extremely useful in diagnosing, tracking, and predicting the course of multiple sclerosis (MS). Several promising candidate biomarkers suitable for clinical application in MS are under research. Caroline Pot, MD, Lausanne University, Center for Research in Neuroscience, Lausanne, Switzerland, highlights blood neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP) as promising biomarkers for MS as well as novel MRI techniques to follow patients. This interview took place at the European Academy of Neurology (EAN) 2022 Congress in Vienna, Austria.